Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · IEX Real-Time Price · USD
58.74
+0.50 (0.86%)
At close: Jul 19, 2024, 4:00 PM
59.00
+0.26 (0.44%)
Pre-market: Jul 22, 2024, 7:28 AM EDT
Legend Biotech Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Legend Biotech stock have an average target of 80.54, with a low estimate of 60 and a high estimate of 94. The average target predicts an increase of 37.11% from the current stock price of 58.74.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Legend Biotech stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 5 |
| Buy | 5 | 6 | 7 | 6 | 7 | 8 |
| Hold | 2 | 2 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 12 | 12 | 11 | 11 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $73 | Strong Buy | Reiterates | $73 | +24.28% | Jul 18, 2024 |
| TD Cowen | TD Cowen | Strong Buy Maintains $71 → $67 | Strong Buy | Maintains | $71 → $67 | +14.06% | Jul 15, 2024 |
| BMO Capital | BMO Capital | Buy Maintains $90 | Buy | Maintains | $90 | +53.22% | Jul 3, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $73 | Strong Buy | Reiterates | $73 | +24.28% | Jul 3, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $86 | Buy | Reiterates | $86 | +46.41% | Jun 21, 2024 |
Financial Forecast
Revenue This Year
534.94M
from 285.14M
Increased by 87.60%
Revenue Next Year
1.06B
from 534.94M
Increased by 98.90%
EPS This Year
-1.28
from -2.94
EPS Next Year
-0.58
from -1.28
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 649.0M | 1.4B | 2.3B | 3.1B | 3.7B |
| Avg | 534.9M | 1.1B | 1.7B | 2.3B | 2.9B |
| Low | 434.3M | 824.6M | 1.1B | 1.8B | 2.2B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 127.6% | 166.6% | 114.8% | 80.2% | 61.4% |
| Avg | 87.6% | 98.9% | 59.8% | 36.5% | 24.9% |
| Low | 52.3% | 54.1% | 1.7% | 7.2% | -6.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.74 | 0.63 | 2.45 | 3.85 | 4.76 |
| Avg | -1.28 | -0.58 | 1.08 | 1.85 | 2.87 |
| Low | -2.05 | -1.55 | 0.04 | 0.77 | 1.31 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 256.5% | 156.4% |
| Avg | - | - | - | 71.6% | 54.6% |
| Low | - | - | - | -28.4% | -29.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.